Poltreg Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 34

Employees

  • Stock Symbol
  • PTG

Stock Symbol

  • Share Price
  • $4.89
  • (As of Friday Closing)

Poltreg General Information

Description

Poltreg SA is a biotechnology company is a Polish biotechnology company developing therapies using regulatory T cells (TREGS) - which have applications in the field of autoimmunity - including in the treatment of type 1 diabetes (CT1), multiple sclerosis and others. It focuses on the clinical trials and the commercialization of a patented method of T-regulator lymphocyte prolife ration for the treatment of type 1 diabetes in children. The company's operations are mainly conducted in Poland.

Contact Information

Website
www.poltreg.bio
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Botaniczna 20
  • Gdańsk, 80-298
  • Poland
+48 512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
WAR
Vertical(s)
Corporate Office
  • Botaniczna 20
  • Gdańsk, 80-298
  • Poland
+48 512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Poltreg Stock Performance

As of 13-Nov-2026, Poltreg’s stock price is $4.89. Its current market cap is $28.9M with 5.92M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.89 $4.85 $4.31 - $8.08 $28.9M 5.92M 4.43K -$1.37

Poltreg Financials Summary

As of 30-Jun-2026, Poltreg has a trailing 12-month revenue of $65.9K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 26,620 27,085 31,006 40,892
Revenue 66 0 88 333
EBITDA (5,103) (5,493) (4,049) (3,648)
Net Income (6,714) (6,909) (4,696) (3,224)
Total Assets 19,998 20,266 24,892 31,848
Total Debt 1,989 2,117 1,938 2,053
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Poltreg Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Poltreg‘s full profile, request access.

Request a free trial

Poltreg Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Poltreg SA is a biotechnology company is a Polish biotechnology company developing therapies using regulatory T cells (T
Drug Discovery
Gdańsk, Poland
34 As of 2026

Suresnes, France
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Poltreg Competitors (18)

One of Poltreg’s 18 competitors is Egle Therapeutics, a Venture Capital-Backed company based in Suresnes, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Egle Therapeutics Venture Capital-Backed Suresnes, France
Lyell Immunopharma Formerly VC-backed South San Francisco, CA
Enterome Venture Capital-Backed Paris, France
Seres Therapeutics Formerly VC-backed Cambridge, MA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
You’re viewing 5 of 18 competitors. Get the full list »

Poltreg Patents

Poltreg Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025219454-A1 Preproinsulin tolerogenic fragments for treating and monitoring type 1 diabetes Pending 18-Apr-2024
EP-4544303-A1 Methods for monitoring and for assessing the efficacy of treg cell therapies Pending 11-Sep-2023
US-20260185983-A1 Methods for monitoring and for assessing the efficacy of treg cell therapies Pending 11-Sep-2023
WO-2025056144-A1 Methods for monitoring and for assessing the efficacy of treg cell therapies Inactive 11-Sep-2023
EP-3985105-A1 Conditioned regulatory t cell population tregs with enhanced therapeutic potential, method for obtaining of conditioned tregs and the medical use of the tregs population Pending 16-Oct-2020 A61K40/48
To view Poltreg’s complete patent history, request access »

Poltreg Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Poltreg Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Poltreg‘s full profile, request access.

Request a free trial

Poltreg ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Services

Subindustry

Rank

Percentile

To view Poltreg’s complete esg history, request access »

Poltreg FAQs

  • When was Poltreg founded?

    Poltreg was founded in 2015.

  • Where is Poltreg headquartered?

    Poltreg is headquartered in Gdańsk, Poland.

  • What is the size of Poltreg?

    Poltreg has 34 total employees.

  • What industry is Poltreg in?

    Poltreg’s primary industry is Drug Discovery.

  • Is Poltreg a private or public company?

    Poltreg is a Public company.

  • What is Poltreg’s stock symbol?

    The ticker symbol for Poltreg is PTG.

  • What is the current stock price of Poltreg?

    As of 13-Nov-2026 the stock price of Poltreg is $4.89.

  • What is the current market cap of Poltreg?

    The current market capitalization of Poltreg is $28.9M.

  • What is Poltreg’s current revenue?

    The trailing twelve month revenue for Poltreg is $65.9K.

  • Who are Poltreg’s competitors?

    Egle Therapeutics, Lyell Immunopharma, Enterome, Seres Therapeutics, and Sangamo Therapeutics are some of the 18 competitors of Poltreg.

  • What is Poltreg’s annual earnings per share (EPS)?

    Poltreg’s EPS for 12 months was -$1.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process